ArticleEuropean journal of nuclear medicine and molecular imaging2026
FAP-targeted [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePositron emission tomography (PET) using fibroblast activation protein inhibitors (FAPI) has emerged as a robust imaging tool for solid tumours. The novel ligand [68Ga]BED003 (formerly known as [68Ga]Ga-OncoFAP-DOTAGA) has demonstrated very high affinity for the fibroblast activation protein and favourable biodistribution. This study aimed to assess the in vivo distribution of [68Ga]BED003 across a spectrum of solid tumours as a potential prerequisite for radioligand therapy.
methodsIn this retrospective analysis, [68Ga]BED003 PET/CT or PET/MRI of 157 patients with 19 different solid malignancies were retrospectively analysed. A spherical volume of interest (VOI) was placed over the primary tumour, the most intense lymph node and distant metastases that were evaluated as at least likely malignant in the written reports, and the maximum standardized uptake value (SUVmax) was derived. Liver and blood pool background mean SUV (SUVmean) were assessed using standardised VOIs. Tumour-to-background ratios (TBRmax) were calculated as the ratio of SUVmax to background SUVmean. SUVmax and TBRmax values of primary tumours, lymph node, and distant metastases were compared using Wilcoxon rank-sum and signed-rank tests, as appropriate.
resultsOverall, 115 primary tumours, 70 lymph node metastases, and 116 distant metastases were analysed, yielding median SUVmax of 16.6, 12.3, and 11.9, respectively. No significant difference in SUVmax or TBRmax were observed between lymph node and distant metastases (all P > 0.05). In contrast, primary tumours demonstrated significantly higher uptake than lymph node and distant metastases (all P < 0.001), except for liver TBRmax when comparing primary tumours with lymph node metastases (P > 0.05). Across all 301 lesions, the median SUVmax, liver TBRmax and blood pool TBRmax was 14.7 (range, 4.2–35.9), 21.6 (range, 4.2–62.8) and 11.1 (range, 3.0–33.4), respectively. The highest median SUVmax and TBRmax (both) in cohorts with > 5 lesions were found in medullary thyroid, oesophageal, ovarian, cervical, breast, colorectal, and hepatocellular cancers.
conclusion[68Ga]BED003-PET demonstrated consistently high uptake across diverse solid malignancies, supporting its potential role as a tool for multi-cancer diagnostic imaging and patient selection for FAP-targeted radioligand therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.